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Prostate cancer is the second most common tumor in men in the United States.
The annual mortality rate has slowly declined over the past years possibly related to
improved screening and curative treatment for early stage disease. Unfortunately, men
with metastatic disease have a 5-year survival rate of only 28% compared to ~100%
for local and regional stage diseases.1 This large discrepancy is due to the development of castrate-resistant metastatic disease, a more aggressive lethal phenotype with
a distinct biology from castrate-sensitive tumors.
Until this past decade, there were few treatment options available to clinicians
treating metastatic castration-resistant prostate cancer (mCRPC). The leading treatments were estramustine and mitoxantrone, both of which had little objective data for
response. In 2004, the US Food and Drug Administration (FDA)-approved docetaxel
as the first chemotherapeutic agent with overall survival (OS) benefit in mCRPC.2
In the past 6 years, the treatment arsenal of agents that improve OS in mCRPC has
rapidly expanded to include sipuleucel-T, abiraterone, enzalutaminde, radium-223,
and cabazitaxel. Currently, these agents are given sequentially, at the discretion of the
treating physician, with little objective information other than the medical comorbidities and choice of the patient, in driving treatment sequence decisions. Although in
the future, biomarker data may more globally inform sequencing of prostate cancer
therapy, currently physician and patient preference drive most treatment decisions.
In this review, we focus on the clinical development of cabazitaxel and analyze
data demonstrating its benefit on OS in men with mCRPC and data that may help
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Abstract: Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic
castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new
antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are
now multiple effective and approved agents for this disease state. The optimal sequencing of
these agents is unclear as there are no large-scale head-to-head comparisons. Clinicians must
familiarize themselves with the most recent studies as well as drug toxicities to determine the
best treatment option for their patients. In this review, we focus on the development of cabazitaxel for mCRPC, evaluate its efficacy, and highlight key strategies for toxicity management.
Additionally, we summarize the studies that address cabazitaxel treatment sequencing and
optimal dosing schedule.
Keywords: sequencing, clinical trials, docetaxel, abiraterone, enzalutamide, biomarkers
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practitioners with sequencing, dose modifications, and patient
selection for cabazitaxel therapy.
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Mechanism of action
Taxane chemotherapy significantly changed the treatment
landscape in mCRPC. In addition to inducing apoptosis by
microtubule disruption, taxanes have been shown to decrease
translocation of the androgen receptor (AR) to the nucleus in
prostate cancer cells as well as decrease transcription of the AR
protein.3 Docetaxel proved to be a potent semisynthetic taxane
analog in mCRPC, improving OS when compared to the historic standard mitoxantrone, and it remained the only standard
in mCRPC for over a decade.2 Unfortunately, use of the drug
was limited for many patients due to treatment intolerance from
neuropathy, serositis, or refractory cytopenias. Additionally,
acquired tumor resistance to docetaxel and cases of primary resistance were recognized as limitations for its continued use.
Cabazitaxel was developed due to its ability to overcome
tumor resistance to taxanes. Preclinical models of multidrugresistant human and murine cancer cell lines demonstrated
improved cytotoxicity with cabazitaxel compared to docetaxel.
Unlike its parent drugs, cabazitaxel has poor binding to the adenosine triphosphate-dependent drug efflux pump P glycoprotein
(P-gp) 1.4 This allows the drug to accumulate intracellularly at
greater concentrations than docetaxel and is thought to be part
of the mechanism for improved cabazitaxel cytoxicity.5

Cabazitaxel clinical development
Cabazitaxel (formerly XRP6258) was initially tested in a
Phase I trial in 25 patients with metastatic solid malignancies, eight of whom had mCRPC. Participants had two
or fewer previous lines of therapy and 32% had previous
taxane exposure.4 Doses were escalated from 10 mg/m2 to
the maximum tolerated dose of 25 mg/m2 and limited due
to neutropenia events. Interestingly, four patients achieved
a partial response, two of whom had mCRPC.

Cabazitaxel in the second line and
beyond
These data supported the initiation of the international Phase
III TROPIC trial, which opened in 2007.6 Seven hundred
fifty-five men with mCRPC who had disease progression
by Response Evaluation Criteria in Solid Tumor (RECIST)
or prostate specific antigen (PSA) criteria during or after
docetaxel were randomized to treatment with mitoxantrone
(12 mg/m2) and prednisone 10 mg daily vs cabazitaxel
(25 mg/m2) and prednisone. Therapy was given once every
3 weeks, and the primary end point was OS.
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The patient characteristics between both arms were
comparable, with 50% of the study population having measurable soft tissue disease and 25% with visceral disease. Following enrollment of the first 59 patients, inclusion criteria
were amended to exclude patients treated with ,225 mg/m2
cumulative dose of docetaxel, in accordance with updated
docetaxel guidelines recommending at least 12 weeks of
therapy prior to making treatment change decisions. With a
median follow-up of 12.8 months, the primary end point of
OS in the intent to treat population was 15.1 months in the
cabazitaxel group compared to 12.7 months in the mitoxantrone group, demonstrating a 30% relative risk reduction
of death (P,0.0001). Progression-free survival (PFS) was
also statistically better in the cabazitaxel group compared
with the mitoxantrone group (2.8 vs 1.4 months, P,0.0001).
A subgroup analysis showed that patients with measurable
disease had significantly better tumor response rate (14.1%
vs 4.4%, P=0.0005) and PSA response rate with cabazitaxel
compared with mitoxantrone (39.2% vs 17.8%, P=0.0002).
As demonstrated in the Phase I trial, there was a high rate of
febrile neutropenia compared to mitoxantrone (8% vs 1%).
Nonhematological adverse events with cabazitaxel were
similar to that in the Phase I study with 47% diarrhea and
37% fatigue. The rate of neuropathy in this cohort was only
14%. In general, dose reductions were more common in the
cabazitaxel group; however, more cycles of cabazitaxel were
delivered compared to mitoxantrone (6 vs 4).
Though OS was improved with cabazitaxel, there were
18 treatment-related deaths compared to 9 deaths with
mitoxantrone. The most common cause of death was neutropenic sepsis (7/18 deaths). Supportive growth factor was
not permitted with cycle 1 of therapy, but management of
neutropenia thereafter was at the discretion of the treating
physician per guidelines. There were five cardiac-related
deaths on the cabazitaxel arm, with none reported in the
mitoxantrone-treated subjects. Given the overall benefit,
the FDA-approved cabazitaxel for men with mCRPC with
disease progression following docetaxel in 2010.
Subsequent use of cabazitaxel, such as in the German
Compassionate use Programme, employed closer complete
blood count monitoring, with 17.1% of patients treated with
granulocyte colony stimulating factor (G-CSF).7 There was
1.8% incidence of neutropenic fever among 111 patients, with
four infection- or hematological-related deaths reported. In the
United Kingdom Early Access Programme (UK EAP), 112
docetaxel refractory patients were treated with cabazitaxel
25 mg/m2.8 Primary G-CSF prophylaxis was recommended
as per American Society of Clinical Oncology guidelines
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and was administered in 79.5% of patients initially and,
subsequently, a total of 84.8% of patients received G-CSF.
The neutropenic sepsis rate was low (6.3%), occurring in
patients not treated with prophylactic growth factor, and
there were four infection-related deaths. Interestingly, there
were no grade 3/4 cardiac events and patients experienced a
trend toward pain improvement on self-reported quality of
life studies. In a subset analysis of 746 men enrolled in compassionate use and early access programs, safety, as reported
based on age, ,70, 70–74, and .75 years was reviewed.9 In
a multivariable analysis, patients aged .75 years and those
with neutrophil count ,4,000/mm3 at baseline were at the
highest risk of neutropenia and complications and prophylactic G-CSF mitigated these risks.

Cabazitaxel dose selection
The FDA-approved dose of cabazitaxel (25 mg/m2) was
based on the TROPIC trial, but questions remained whether a
lower dose could still be as efficacious with less toxicity. This
led to the FDA-mandated PROSELICA study, a randomized
Phase III noninferiority study of cabazitaxel 20 mg/m2 (C20)
vs 25 mg/m2 (C25) in 1200 patients with mCRPC previously
treated with docetaxel (D).10 Of the 10 planned treatments,
both groups completed a similar number of median cycles
of therapy, 6 (C20) and 7 (C25), with more dose reductions
in the 25 mg/m2 arm. There were more grade 3/4 treatmentrelated toxicities and more treatment-related deaths in C25
compared to C20. However, a sub group analysis showed that
patients treated with prior second-generation antiandrogens
(enzalutamide or abiraterone) had a trend toward better outcomes with C25 than C20. Patients treated on the 25 mg/m2
arm had significantly improved PSA response rates (42.9%
vs 29.5%, P,0.001) and improved radiographic response,
but there was no difference in PFS. OS was 13.4 months in
the C20 arm, which was not inferior to 14.5 months in the
C25 cohort (hazard ratio [HR] 20 vs 25, HR=1.024). This
met the FDA-mandated prespecified noninferiority endpoint,
which maintained 50% of the OS benefit of the C25 dose in
the originally reported TROPIC trial.
Alternative cabaztiaxel dosing regimens that have been
explored include a weekly schedule for “unfit” mCRPC
patients. Investigators defined unfit as patients with Eastern
Cooperative Oncology Group status .2, history of dose
reduction with docetaxel due to febrile neutropenia, or
history of radiation affecting .25% of the bone marrow
reserve. MTD had previously been established as cabazitaxel
10 mg/m2 given for 4 weeks on a 5-week cycle.11 Sixty-six
unfit patients with mCRPC were evaluated, 87% of whom
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had metastatic bone disease. Overall, treatment was well
tolerated. The most common grade 3/4 toxicities were
asthenia (10.6%), anemia (6%), thrombocytopenia (4.5%),
and neutropenia (3%). There were no occurrences of febrile
neutropenia or grade 4 diarrhea. A decline in PSA by 50%
was observed in 32.7%. The median OS with weekly dosing
was 14.2 months, making this regimen a reasonable option
for patients with an impaired performance status.12

Treatment sequencing
Determining the ideal sequencing of therapy is difficult, as
there are no prospective head-to-head trials evaluating all
the available treatments for mCRPC. Comparison between
individual trials certainly has its own limitations as studies
vary in their design, comparator arm, and patient characteristics. As such, clinicians rely heavily on large retrospective
analyses to draw conclusions for optimal therapy sequencing post-docetaxel. To date, no clear prospective data exist
to support a sequence of subsequent therapy following
docetaxel.

Cabazitaxel following second-generation
hormone therapy
Though the sequence and biological rationale for the use of
docetaxel followed by cabazitaxel is clear, little is known
about resistance mechanisms and optimal sequencing of the
other FDA-approved agents for mCRPC. There is a suggestion that resistance to abiraterone may also confer cross
resistance to docetaxel, but this is not known for cabazitaxel.13
In the aforementioned PROSELICA trial, patients who were
previously treated with abiraterone or enzalutamide experienced significantly better rates of PSA response and radiographic responses with cabazitaxel 25 mg/m2 compared to
those treated with 20 mg/m2, though no survival differences
were noted. These are probably the most robust prospective
data on the sequence of cabazitaxel with second-generation
androgen inhibitors.
Several retrospective studies have addressed the activity
of cabazitaxel following abiraterone. In a multicenter retrospective Israeli study in subjects on abiraterone compassionate use programs following docetaxel, 24 patients received
subsequent cabazitaxel for a median of four cycles.14 Most
patients were treated with growth factor support at the outset
of therapy. A PSA response of .50% decline from baseline
was seen in 31% of patients, and RECIST response was seen
in 13% of patients, with a median survival of 8.2 months
from initiation of cabazitaxel, thus supporting its activity
after progression on abiraterone.
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In a single-center retrospective study from the Royal
Marsden Hospital, 59 patients who had progressed after
docetaxel and who had received cabazitaxel for mCRPC
were identified. Thirty-two patients had received prior
abiraterone for a median of 7 months, four patients had prior
enzalutamide for a median of 1 month, and five patients had
received both.15 A median of six cabazitaxel cycles were
delivered, with an OS of 15.8 months, similar to that reported
in the TROPIC study. Lack of response to initial abiraterone
and enzalutamide therapy in this retrospective study did not
appear to influence the response to cabazitaxel.
In a French and Canadian study, 79 men with mCRPC
were treated with a median of six cycles of cabazitaxel
25 mg/m2 post a median of eight cycles of docetaxel and
4.8 months of abiraterone.16 Patients experienced an OS of
10.9 months, and PSA decline .50% in 35% of patients.
In a retrospective series from the US Oncology Practice
Network, sequences of docetaxel, cabazitaxel, and abiraterone were reviewed.17 One hundred thirteen patients received
all three agents, of whom 77 patients sequenced docetaxel
(D), followed by cabazitaxel (C), followed by abiraterone (A)
and 36 patients were treated in the DAC sequence. Patients
tolerated more cycles in the DCA compared to the DAC
sequence (six vs four cycles, P,0.001), with improved OS in
the DCA sequence as well (18.2 vs 11.8 months, P=0.0023).
The authors speculate that the additional cycles of cabazitaxel tolerated may contribute to the clinical benefits of the
DCA sequence.
Finally, the impact of previous treatment with secondgeneration androgen inhibition on cabazitaxel efficacy was
evaluated in a Phase II Dutch trial of cabazitaxel 25 mg/m2
with prednisone, with or without budesonide to prevent
chemotherapy-induced diarrhea.18 Forty-four of 114 evaluable patients had received either enzalutamide (3), abiraterone (39), or both (2) following docetaxel, prior to initiating
cabazitaxel while the remainder (70) proceeded directly
to cabazitaxel after docetaxel failure. Other than slightly
lower albumin, there were no baseline differences between
those who had and had not received a second-generation
therapy. There were no significant differences in rates of PSA
response .50% to cabazitaxel between the groups treated
with and without second-generation antiandrogen agents
(34% vs 40%, P=0.53), or there was a significant difference
in the median OS of 13 vs 14 months.
These retrospective studies help highlight the efficacy
of cabazitaxel in mCRPC patients who failed docetaxel and
AR-directed therapies, suggesting that the mechanism of resistance for each may be different. Identifying mCRPC patients
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who may benefit from earlier initiation of cabazitaxel was
an integral driving force behind the prospectively designed
TAXYNERGY trial.19 Investigators looked at overcoming
inherent taxane resistance in chemotherapy-naive mCRPC
by utilizing an early switch model. Patients previously treated
with AR therapies (44.4%), radiation, or immunotherapy were
randomized 2:1 to docetaxel or cabazitaxel and re-evaluated
at 12 weeks for PSA decline of $30% from baseline. If PSA
did not drop sufficiently, they were switched to the other
taxanes. Primary endpoint was to improve upon the historical
PSA response rate (.50% decline) observed in the TAX327
of 45.4%. In an intention to treat analysis, 55.6% of patients
achieved a PSA decline of .50% by the end of the study
reaching statistical significance. PSA response rate in patients
previously treated with AR therapies was lower (44%) than
AR-naive patients (68%). Fifteen of 63 patients switched
taxane therapy after 12 weeks due to poor PSA response and
46.7% (7) of these patients achieved a PSA decline of .50%.
Median OS was not reached. Correlation of patient response
with circulating tumor cells (CTCs) is described later (refer
“Biomarkers of efficacy” section). Further trials to determine
benefit of early taxane switching in mCRPC are warranted with
a focus on patients who have failed AR-directed therapies.

Cabazitaxel prior to second-generation
hormone therapy
While cabazitaxel seems to retain activity after exposure to
abiraterone or enzalutamide, several studies have evaluated
the impact of using it prior to these hormonal agents. In the
multicenter retrospective CAST study from the Netherlands,
patients with mCRPC following docetaxel were treated with
cabazitaxel and abiraterone sequential therapy.20 Sixty-three
men received cabazitaxel followed by abiraterone (CA), and
69 were treated in the reverse sequence (AC). There was
a significant difference in baseline age, with the median
age of the CA patients 65.6 years and the mean age of AC
patients 69.8 years (P,0.001). Apart from age, there were
no other baseline tumor-related differences and both groups
received similar number of prior docetaxel cycles. In the CA
group, men received a mean of 7.3 cabazitaxel cycles, which
was significantly more compared to 4.6 in the AC group
(P,0.001). There was no significant difference in OS based
on treatment sequence, with median OS 19.1 months for CAtreated patients and 17.0 months for AC-sequenced patients.
Hospitalization for febrile neutropenia occurred in 9.5% CA
patients and 14.5% AC-treated individuals, and there were
more deaths within 30 days in the CA when compared to the
AC sequence, though most were due to disease progression.
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Contrary to the CAST study, the results from a large
retrospective Italian study seemed to suggest a slight survival
advantage when cabazitaxel (C) was used prior to a secondgeneration novel hormone therapy (NHT) abiraterone and
enzalutamide.21 Four-hundred seventy-six patients with
mCRPC who had received at least two therapies post-docetaxel (D) were grouped by treatment history: D–NHT–C,
D–C–NHT, and D–NHT–NHT. The median OS from initiation of the second agent was statistically significant at 12.9,
14.2, and 8.8 months, respectively (P=0.01) with the longest
OS in the patients treated with cabazitaxel in the second
line. Investigators did not report on the median number
of cycles of cabazitaxel for each group, but this might be
a critical factor that can help explain the OS benefit in the
D–C–NHT group.
Similar results were seen with a retrospective review of
574 mCRPC cases from the FLAC international database.22
Patients again were separated into groups based on their
treatment history: Group 1: D–C–NHT; Group 2: D–NHT–C;
and Group 3: D–C. The median number of cycles was 7 for
docetaxel and 6 for cabazitaxel. The OS from first docetaxel
cycle was 40.1, 37.1, and 30.1 months, respectively. Investigators note that the activity of cabazitaxel did not seem to
be influenced by prior NHT use. Although the trend supports
improved outcomes with cabazitaxel in the second line, the
data are retrospective and the possibility of a patient selection bias toward healthier patients must be recognized. This
concern is reinforced by the multivariate analysis that showed
patients with a lower PSA, longer ADT response times, and
lack of clinical progression at the time of docetaxel initiation
overall had a better prognosis.

Rechallenging patients with cabazitaxel
Data regarding cabazitaxel rechallenge in fit patients with
history of good response are limited, but one retrospective
study looked at 70 mCRPC patients previously treated with
docetaxel (D), cabazitaxel (C), and a second-generation antiandrogen who were retreated with cabazitaxel.23 A majority
of the patients (74%) had received D–NHT–C, while 24%
received D–C–NHT. The median time from last cabazitaxel
dose was 8.6 months. Rechallenge doses of cabazitaxel
every 3 weeks were 25 mg/m2 (58% of patients), 20 mg/m2
(27%), and 16 mg/m2 (14.3%). Less than half (47%) of the
patients required growth factor support. The mean PFS was
7.8 months with an OS of 13.4 months from initiation of
rechallenge. Grade 3/4 toxicities were 18%, and there were no
episodes of febrile neutropenia. As investigators remarked,
these promising data may be skewed by patient selection
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bias, given that all participants were assessed to be fit for
chemotherapy despite at least three other lines of therapy.

Cabazitaxel in the first-line treatment of
mCRPC
In 2016, a large-scale trial provided information on cabazitaxel compared to docetaxel for first-line treatment in
chemotherapy-naive patients in the FIRSTANA study.24 This
was a three-arm trial comparing two doses of cabazitaxel, 20
and 25 mg/m2, to docetaxel 75 mg/m2 in men with chemotherapy-naive mCRPC. A total of 1168 patients at 159 centers
participated, very few of whom were previously treated with
second-line hormone therapy. The primary endpoint was OS,
and it was hypothesized that cabazitaxel would be superior to
docetaxel. The study failed to meet this superiority primary
endpoint, as there was no difference in OS between cabazitaxel and docetaxel at either dose, with survival ranging
from 24.3 to 25.2 months between the groups, and there was
no difference in PFS. The median number of cycles was 9.
Dose delays and reductions were highest in the cabazitaxel
25 mg/m2 arm, as were rates of neutropenic fever, infections,
diarrhea, and hematuria. Peripheral neuropathy, stomatitis,
edema, alopecia, and nail changes were more pronounced
in the docetaxel arm compared with the cabazitaxel arm
(Table 1). These data continue to support the use of docetaxel as first-line therapy of patients with mCRPC. The
discussant of this important and informative Phase III trial,
Dr Raghavan, also reviewed the significant cost difference
between docetaxel and cabazitaxel, highlighting the value,
as well as safety and efficacy of docetaxel in the first line.25
More prospective, randomized trials of cabazitaxel in the
first line are in progress and will hopefully clarify where it
belongs in treatment sequencing of mCRPC.
Table 1 FIRSTANA (NCT01308567) side effect profile of
docetaxel vs cabazitaxel as first-line treatment in mCRPC
TEAEs .5%

Docetaxel
75 mg/m2 (%)

Cabazitaxel
25 mg/m2 (%)

All grades Grade 3/4 All grades Grade 3/4
Febrile neutropenia
Neutropenic infection
Diarrhea
Stomatitis
Hematuria
Peripheral neuropathy
Peripheral edema
Alopecia
Nail disorders

8.3
4.9
37
13.7
3.6
25.1
20.4
39
9

8.3
4.1
2.3
0.8
0.3
2.1
1.6
0
0.3

12
6.1
49.9
6.6
25.1
12.3
7.7
13
0.8

12
5.9
5.6
0.3
3.6
0
0.3
0
0

Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; TEAEs,
treatment-emergent adverse events.
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Cabazitaxel in combination with a second
agent
Several trials have tried to enhance the antitumor activity of
cabazitaxel by adding a second agent with a distinct mechanism
of action. Researchers propose that targeting prostate cancer
cells in two separate ways will lead to greater cytotoxicity
and diminish chances for developing resistance. In the Phase
III Affinity trial, investigators randomized 635 mCRPC
patients who had failed docetaxel to cabazitaxel ± curtisen
(OGX-011), a novel agent designed to inhibit the production
of clusterin, a cytoprotective protein that is upregulated in
cancer cells exposed to chemotherapy.26 Cabaztiaxel was
given once every 3 weeks at 25 mg/m2 and curtisen was given
weekly at 640 mg intravenously for a total of 10 cycles. The
study unfortunately did not reach its primary endpoint of OS
(14.2 vs 13.4 months; P=0.529).
Cabazitaxel is also being studied with a small-molecule
inhibitor tasquinimod in the Phase I CATCH trial.27 Tasquinimod limits the activity of myeloid-derived suppressor cells
(MDSCs), which accumulate in the tumor microenvironment
and inhibit the antitumor activity of T, natural killer, and dendritic cells. The small molecule binds to protein S100A8/A9
and interrupts the positive feedback of further MDSC recruitment. The study established a maximum tolerated dose (MTD)
of cabazitaxel 25 mg/m2 and tasquinimod 0.5 mg daily with a
lead-in of 0.25 mg daily for 3 weeks. Observed grade 3/4 events
were fatigue, febrile neutropenia, and liver dysfunction.
In addition to novel drugs, cabazitaxel is being studied in
combination with other agents used in mCRPC. Single-arm,
early-phase trials have demonstrated the tolerability and
efficacy of cabazitaxel at 25 mg/m2 every 3 weeks with abiraterone 1,000 mg daily.28 These include patients previously
treated with docetaxel and at least 3 months of abiraterone. Of
the 26 patients, 46.2% achieved a PSA response, which was
higher than the historic controls seen with abiraterone alone
(29%) and cabazitaxel alone (39%). The median PSA–PFS
was 6.9 months, and a subset of patients (6) had a sustained
PSA response at 6 months. Adverse events observed were
similar to those seen with the drugs individually. Additional
randomized studies of cabazitaxel and abiraterone are ongoing
as are early-phase studies of cabazitaxel with enzalutamide.
Cabazitaxel has also been paired with other chemotherapy
agents such as carboplatin with the hypothesis that patients
with aggressive variant of prostate cancer (AVPC) may have
better outcomes with a taxane–platinum combination.29 Previous work by Aparicio et al identified the presence of at least
two mutations in p53, Rb1, and/or PTEN in androgen indifferent tumor samples and postulated that their presence would
4094
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correlated with platinum response. Clinical characteristics of
AVPC were defined as histological presence of small cell,
visceral, or lytic bone disease at presentation, bulky tumor,
or adenopathy, PSA ,10, despite high disease burden. One
hundred sixty men were randomized to cabazitaxel 25 mg/m2
± carboplatin at area under the curve 4 every 3 weeks. Median
PFS was significantly better in the combination arm at 7.0 vs
4.6 months for cabazitaxel alone (P=0.004). This benefit was
greater in those patients with AVPC with median PFS 8 vs
4.5 months (P=0.0036). Molecular profiling of tumor biopsies and ctDNA are in process, but early results suggest that
the molecular definition on AVPC better predicts response to
platinum–taxane therapy compared to the clinical definition.
Investigators are planning a Phase III trial powered for OS.

Biomarkers of efficacy
In a post hoc analysis of the patients treated with cabazitaxel
on the TROPIC study, those who developed grade .3 neutropenia had significantly prolonged OS (16.3 vs 14 months,
P=0.035), PFS (5.3 vs 2.6 months), and a higher rate of PSA
response of .50% than those who did not.30 There was a trend
that the frequency of neutropenia was associated with OS and
PFS. The authors also observed the effect of neutrophil-tolymphocyte ratio (NLR) upon outcomes and defined high
baseline NLR .3 and low ,3. Analyzed together, those
with grade .3 neutropenia and low NLR experienced the
longest OS of 19.2 months, while those with high NLR and
no neutropenia had a 12.9-month OS. In the minority of
patients treated with G-CSF after cycle 1 in TROPIC, there
did not seem to be an effect upon survival. These authors
suggest that a tailored approach to cabazitaxel dosing based
on neutropenia may enhance patient outcomes.
With the advent of precision medicine, research has
focused on the development of predictive biomarkers to aid
in treatment selection. Presence of the AR splice variant 7
(AR-V7) in CTCs from men with mCRPC appears to correlate with treatment resistance to abiraterone and enzalutamide.31 Several investigators have sought to determine if
the same resistance is true for chemotherapy as well. Thirtyseven men starting either docetaxel or cabazitaxel chemotherapy were prospectively evaluated at a single institution
to determine if AR-V7 in CTCs was correlated to clinical
outcomes.32 There were no significant differences between
subjects with and without measurable AR-V7 with respect
to response to taxane chemotherapy; however, as expected,
AR-V7-positive men responded better to taxanes than to
second-generation hormone therapy.
CTCs were also studied in the aforementioned
TAXYNERGY trial. Investigators hypothesized that
OncoTargets and Therapy 2017:10
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taxane-sensitive tumor cells would have a decrease in AR
nuclear localization (ARNL) due to disruption of microtubule
activity. The ARNL percentage in CTCs was measured on
days 1 and 8 of cycle 1 of taxane therapy. A taxane-induced
decrease in mean percentage of ARNL significantly correlated with a higher rate of PSA response of $50% decline
in PSA (72.2% vs 12.5%, P=0.009). This evidence supports
preclinical data that the anti-tumor activity of taxanes in prostate cancer is related to their disruption of AR trafficking from
the cytoplasm to the nucleus and suggests that persistence
of ARNL in setting of taxane treatment may be a marker of
therapy resistance.19 Larger studies are needed to corroborate
this potential biomarker of taxane sensitivity.

Patient selection
The development of treatment predictive biomarkers is a promising field but is still under investigation in prostate cancer.
Based on the above studies, cabazitaxel should be reserved off
trial for men with mCRPC following docetaxel. Retrospective
data suggest that it retains significant activity after progression
on second-generation antiandrogens. Proactive management

of toxicity, specifically neutropenia, is critical and should
especially be considered in patients older than 75 years with
baseline absolute neutrophil count ,4,000/mm3. Use of
cabazitaxel at lower dose of 20 mg/m2 offers similar OS, but
a subset of patients who tolerate treatment with low NLR may
have better outcomes. Similarly, a low-dose weekly regimen
may be reasonable in patients with Karnofsky Performance
Score ,70%. Rechallenging patients with cabazitaxel who
previously had a good response is a promising option to help
extend survival. With regard to patient preference, prospectively collected data outcomes from the 3,000 men in the
Prostate Cancer Registry showed that patients on abiraterone
or enzalutamide as second-line treatment after docetaxel
reported a higher rate of clinically meaningful improvement
in quality of life compared to those treated with cabazitaxel
despite similar time to disease progression.33 Interestingly, the
cabazitaxel group reported lower rates of clinically meaningful deterioration in their quality of life. To date, the time to
disease progression is similar among all agents.
Ultimately, more prospective data are needed. Tables 2
and 3 briefly describe the latest trials registered on

Table 2 Recently completed clinical trials of cabazitaxel in mCRPC
NCT number

Phase

Description

Single-agent cabazitaxel in mCRPC
NCT01254279
III
UK EAP to assess quality of life and safety data on
cabazitaxel 25 mg/m2 in mCRPC previously treated with
docetaxel8
NCT00417079

III

NCT01649635

IV

TROPIC: cabazitaxel vs mitoxantrone in mCRPC
previously treated with docetaxel6

PROSPECTA: to assess effectiveness of prophylactic
treatment of hematological complications (grade $3
neutropenia) resulting from cabazitaxel treatment in
mCRPC previously treated with docetaxel
NCT02074137
IV
Evaluation of safety of cabazitaxel in patients with
mCRPC previously treated with docetaxel
NCT02441894
IV
PEGAZUS: assess tolerability of cabazitaxel with
primary prophylaxis PEG-G-CSF in mCRPC previously
treated with docetaxel
NCT01324583
I
Dose-escalation study with cabazitaxel and
prednisolone in patients with hormone refractory
prostate cancer previously treated with docetaxel
Cabazitaxel dosing in mCRPC
NCT01308580
III
PROSELICA: cabazitaxel at 20 vs 25 mg/m2 with
prednisone for the treatment of mCRPC10
NCT01541007

II

NCT01518283

II

NCT01558219

II

ConCab: assess tolerability of cabazitaxel 25 mg/m2
every three weeks vs 10 mg/m2 for 5 consecutive
weeks of a 6-week cycle
Study of weekly cabazitaxel for unfit mCRPC12
Safety and efficacy of biweekly dosing of cabazitaxel in
second line treatment of mCRPC34

Results
Almost 1/3 of patients completed $10 cycles in the UK
EAP. QOL was stable with trends to improved EQ-5D and
VAS scores. Improved or stable pain was observed in the
majority of patients continuing therapy
Updated cabazitaxel prolongs OS at 2 years vs mitoxantrone
and has low rates of peripheral neuropathy. Palliation benefits
of cabazitaxel were comparable to those of mitoxantrone
Not posted

Not posted
Not posted

Not posted

Cabaztiaxel 20 mg/m2 demonstrates noninferiority for
OS compared to Cabaztiaxel 25 mg/m2 and an improved
overall safety profile
Not posted

Cabazitaxel 10 mg/m2 weekly is tolerable and effective in
unfit patients and results in OS of 14.2 months
Cabazitaxel 16 mg/m2 biweekly without G-CSF is tolerable
with 16% neutropenia and 1.7% neutropenic infection

(Continued)
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Table 2 (Continued)
NCT number

Phase

Description

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 147.140.233.14 on 19-Sep-2018
For personal use only.

Sequencing of single-agent cabazitaxel in mCRPC
NCT01718353
II
TAXYNERGY: explore the benefit of an early switch
from docetaxel to cabazitaxel and vice versa in mCRPC
who do not achieve $30% PSA decline from baseline
by cycle 4 and correlated with CTCs19

NCT01576029

II

PSA reduction in 55.6% of patients compared to historic
rate of 45.4% in TAX327. Nearly 90% of men with
progressive chemo-naive mCRPC have detectable CTCs
with higher CTC counts associated with adverse prognostic
variables. Lower percent of nuclear AR was associated with
visceral metastases, suggesting that progressive visceral
CRPC may be less AR driven. Decrease in ARNL on day 8
of taxane treatment correlates with PSA response
Not posted

II

Phase I: MTD-cabazitaxel 25 mg/m2 every 21 days with
abiraterone 1,000 mg daily; Phase II: statistically significant
PSA reduction in 46% of patients
Not posted

SWITCH: compare the continuation of treatment with
docetaxel vs switching to cabazitaxel regarding the time
to PSA progression
Cabazitaxel with AR agent in mCRPC
NCT01511536
I and II
Determine MTD and efficacy of cabazitaxel with
abiraterone in mCRPC progressed on docetaxel28
NCT01845792

Results

Study of cabazitaxel with or without abiraterone/
prednisone in mCRPC
Cabazitaxel with other agents in mCRPC
NCT01513733
I
CATCH: determine safety and MTD of tasquinimod
in combination with cabazitaxel in men with
chemorefractory mCRPC27
NCT01505868
II
Study of cabazitaxel with or without carboplatin
(AUC 4) in patients with mCRPC29
NCT01578655
III
AFFINITY: determine if addition of curtisen to cabazitaxel/
prednisone enhances OS and PFS in mCRPC26

MTD established at Cabaztiaxel 25 mg/m2 every 3 weeks
with tasquinimod 0.5 mg daily with a 3-week lead-in at
0.25 mg daily
Combination with significantly better PFS overall
(7 vs 4.6 m) and in aggressive subtype (8 vs 4.5 m)
No statistically significant improvement in OS

Abbreviations: AR, androgen receptor; ARNL, AR nuclear localization; AUC, area under the curve; CRPC, castration-resistant prostate cancer; CTCs, circulating tumor
cells; EQ-5D, Descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression);
G-CSF, granulocyte colony stimulating factor; m, months; mCRPC, metastatic castration-resistant prostate cancer; MTD, maximum tolerated dose; OS, overall survival;
PEG, polyethylene glycol; PFS, progression-free survival; PSA, prostate specific antigen; QOL, quality of life; UK EAP, United Kingdom Early Access Program; VAS, visual
analogue scale.

Table 3 Ongoing clinical trials of cabazitaxel in prostate cancer
NCT number

Phase

Description

Cabazitaxel in high risk or locally advanced disease
NCT01952223
III
PEACE2: assess effect of neoadjuvant cabazitaxel and pelvic XRT with ADT in high-risk localized prostate cancer
NCT01420250
I
Weekly cabazitaxel with IMRT and ADT in locally advanced prostate cancer
NCT01978873
III
SenciCab: cabazitaxel + ADT vs ADT alone in metastatic or high-risk disease
NCT02543255
II
ACDC trial: neoadjuvant cabazitaxel and abiraterone with ADT in high-risk prostate cancer
Cabazitaxel sequencing in mCRPC
NCT01308567
III
FIRSTANA: cabazitaxel vs docetaxel both with prednisone as first line in patients with mCRPC
NCT02044354
III
CABA-DOC: patient preference between first-line cabazitaxel vs docetaxel in mCRPC
NCT02844582
II
Cabazitaxel/prednisone as first line therapy in mCRPC
NCT02254785
II
Compare the clinical benefit of cabazitaxel vs abiraterone or enzalutamide in poor prognosis mCRPC patients
NCT02485691
IV
CARD: compare cabazitaxel vs AR-directed agents in mCRPC previously treated with docetaxel and who
rapidly failed a prior AR agent
NCT02512458
II
CABA-BONE: explore the effect of cabazitaxel on survival pathways and androgen signaling in the tumor
microenvironment (bone marrow) of patients with mCRPC
NCT02903160
II
PRINT: determine the clinical benefits of using a rapidly cycling, non-cross-reactive regimen of FDAapproved prostate cancer therapeutic agents in the management of CRPC
Alternate dosing of cabazitaxel in mCRPC
NCT02961257
III
CABASTY: safety of biweekly cabazitaxel at 16 mg/m2 vs triweekly cabazitaxel at 25 mg/m2 in elderly mCRPC
patients previously treated with docetaxel
Cabazitaxel combined with AR agent in mCRPC
NCT02218606
II
Determine pathologic effects of abiraterone with or without cabazitaxel on mCRPC tissue
NCT02522715
I and II
Assess safety/tolerability of enzalutamide and cabazitaxel combination in mCRPC
NCT03110588
I
PACE: determine the feasibility and recommended dose of the combination of four drugs (prednisone,
abiraterone, and cabazitaxel and enzalutamide as first-line therapy for mCRPC

(Continued)
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Table 3 (Continued)
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NCT number

Phase

Description

Cabazitaxel with other agents in mCRPC
NCT01594918
I
CAMP: assess safety and dosing of cabazitaxel with mitoxantrone and prednisone in mCRPC
NCT02703623
II
DyanMo: safety and effectiveness of drug combinations in mCRPC of apalutamide and abiraterone with
carboplatin and ipilimumab or cabazitaxel
NCT03043989
I
Cohorts of docetaxel or cabazitaxel in combination with potent CYP3A4 inhibitor clarithromycin
Biomarker assessment with cabazitaxel
NCT03050866
II
CABAV7: cabazitaxel in mCRPC patients with AR-V7-positive CTCs
NCT03101046
II
TACTIK: treatment of mCRPC patients according to CTC kinetics
Abbreviations: ADT, androgen deprivation therapy; AR, androgen receptor; AR-V7, AR splice variant 7; CRPC, castration-resistant prostate cancer; CTCs, circulating
tumor cells; CYP3A4, cytochrome P450 3A4; FDA, US Food and Drug Administration; IMRT, intensity modulated radiation therapy; mCRPC, metastatic castration-resistant
prostate cancer; XRT, radiation.

ClinicalTrials.gov that will hopefully provide greater insight
on cabazitaxel sequencing as well as alternate dosing patterns
or in combination with other therapies.

Conclusion
Treatment of mCRPC is dynamic and complex. Until the
development of predictive treatment biomarkers, clinicians
rely on data from prospective clinical trials as well as the
conclusions drawn from retrospective analyses. In this
review, we examine the evidence for the role of cabazitaxel
in mCRPC. The FIRSTANA data continue to support the
chemotherapy sequence of docetaxel followed by cabazitaxel. This is also supported by other retrospective studies.
However, in looking at past and future studies, it is important
to consider that patients sequenced with docetaxel and then
cabazitaxel may be fitter, thus confounding the success of
DC sequencing. Randomized controlled trials are needed to
address this and other variables.
Toxicity from TROPIC and subsequent trials continue to
show that treatment-related neutropenia and complications
remain significant and can be modified by the use of prophylactic growth factor support, particularly for vulnerable
populations of age .75 years and baseline absolute neutrophil count ,4,000/mm3. The PROSELICA data suggest that
use of cabazitaxel at 20 mg/m2 is perhaps a better value when
compared with 25 mg/m2 as it provided a similar survival
outcome with less toxicity. This must be weighed against the
subgroup analysis showing that patients with prior treatment
with abiraterone or enzalutamide had better outcomes on C25
vs C20. At this time, dosing decisions should continue to be
individualized based on the patient’s treatment history and
performance status.
Future directions of cabazitaxel will be determined by
ongoing trials. Its use in combination with AR therapies
and other experimental agents may potentially provide better disease control in mCRPC and help to extend patient
survival.
OncoTargets and Therapy 2017:10
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